TTR and cardiomyopathy: Another notable example is patisiran, an FDA-approved siRNA therapy for patients with hereditary transthyretin-mediated (hATTR; MIM 105210) amyloidosis, a progressive cardiomyopathy caused by heterozygous mutations in the TTR gene (Maurer et al., 2023).